Company Info
NRx is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders. NRx is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior and aims to develop a new drug therapy for post-traumatic stress disorder (PTSD). (taken from already approved language)
NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.
NRx Pharmaceuticals, Inc.
1201 Orange Street
Suite 600
Wilmington, DE 19801
T: 484-254-6134
Investor Relations
Ryan Sheffield
Chief of Staff & Military/Veteran Liaison
T: 484-254-6134 ext. 723
rsheffield@nrxpharma.com
Company Contact
NRx Pharmaceuticals, Inc.
1201 Market Street
Suite 111
Wilmington, DE 19801
T: 484-254-6134
Click here to view our corporate presentation or on the image below
 |
